Two years before those RCTs, Keystone et al. (2004) showed that adalimumab significantly inhibited joint damage and was tolerated well, with one case of lymphoma in the anti-TNF-α group and none in the MTX group [19]. This evidence concerns the gene TNF and lymphoma.